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Abstract
Background: Group B streptococcus (GBS) or Streptococcus agalactiae are members of the normal flora of the
female genital tract. GBS has become the major cause of bacterial infections in the peri-natal period, including
bacteraemia, amnionitis, endometritis, and urinary tract infection in pregnant women as well as sepsis and meningitis
in neonates and young infants. Infection of the new born may be acquired by the intra-amniotic route or directly during
passage through the birth canal.
Objectives: This study was undertaken to determine the prevalence of group B Streptococcus (GBS) colonization and
to analyze related risk factors among pregnant women attending the antenatal clinic of Hawassa Health centre, Adare
Hospital Hawassa, Ethiopia.
Methods: A total of 139 pregnant women were screened for GBS colonization between May and June 2010. Standard
microbiological methods were used to isolate and identify GBS from vaginal and ano-rectal swabs obtained from study
subjects. An antimicrobial susceptibility test was performed for all GBS isolates according to the criteria of the
Clinical and laboratory Standards Institute (CLSI) by disk diffusion method.
Results: A total of 29 out of 139 (20.9%) pregnant women were colonized by GBS. No statistically significant
association was observed for GBS colonization with any of socio-demographic characteristics of the study subjects
including age, occupation, type of contraceptive used, parity, number of antenatal clinic visits. All GBS strains were
susceptible to penicillin, ampicillin, vancomycin and gentamicin.  Resistance was observed against erythromycin
(6.9%), tetracycline (48.2%), ceftriaxone (10.3%), chloramphenicol (51.7%), ciprofloxacin (13.8%) and norfloxacin
(10.3%).
Conclusion: This study showed that prevalence of GBS colonization was 20.9% among the study subjects. The
finding of this study was comparable with findings reported from developed and developing countries. However,
further epidemiological investigations should be done in different parts of the country in order to know the actual GBS
colonization rate in pregnant women and to consider the use of intra-partum antibiotics prophylaxis for prevention of
early onset GBS-neonatal diseases. [Ethiop. J. Health Dev. 2012;26(1):36-42]
Introduction
Since the mid-1960s, group B Streptococcus (GBS) has
become the major cause of bacterial infections in the
peri-natal period, including bacteraemia, amnionitis,
endometritis, and urinary tract infection in pregnant
women as well as focal and systemic infections in
newborns (1). It is a relatively rare cause of infection in
older children and non-pregnant adult women (2). Initial
case series reported case fatality ratios as high as 50%
among new born in USA. In the early 1980s, clinical
trials demonstrated that administering antibiotics during
labor to women at risk of transmitting GBS to their
newborns could prevent invasive disease in the first week
of life (3).
Since the 1970s, GBS has been recognized as the most
important infectious cause of morbidity and mortality in
newborn infants. Despite the decline in mortality during
the past several decades, early onset of GBS disease
remains a serious neonatal condition, which may cause
severe neurological damage (4). Today, it is also the
leading cause of early invasive infections in newborns
worldwide and can also cause life-threatening infections
in pregnant women, in immune-compromised adults, and
apparently in the general population as well (5). Group B
Streptococcus transmission is vertical from mother to
child. The gastrointestinal tract is the source of vaginal
GBS colonized and many adults are colonization with
GBS without showing any symptoms. Approximately
10–30% of women of child bearing age carry GBS in the
recto-vaginal compartment (6). Treatment and prevention
guidelines developed by the Centers for Disease Control
and Prevention (CDC) in 1996 (5) led to a significant
decline in the incidence of early onset of neonatal disease
in institution that adopted and followed these guidelines
strictly (7). The CDC recommendations are to screen the
entire pregnant mothers before term (35-37 weeks of
gestation) and to administer intra-partum prophylactic
antibiotics to all of them. In addition, if the expectant
Mother’s status is not known at labor, chemoprophylaxis
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should be administered to all cases showing one or more
of the main risk factors indicated by the CDC and others
as being significantly related to higher rates of maternally
transmitted neonatal disease (5).
Treatment of colonized mothers succeeded temporarily
eradicating the organism, but most of the women were
re-colonized within 6 weeks. At birth, 50 to 65% of
infants, who were born from colonized mothers had
positive GBS cultures taken from mucus membranes and
skin (external ear canal, throat, umbilicus, ano-rectal
sites) (8). Approximately 98% of the colonized newborns
remained healthy, but 1 to 2% developed invasive GBS
infection (9).
Published information about the prevalence of
colonization by GBS among pregnant women in Ethiopia
is scarce (10). Therefore the present study was conducted
to determine its magnitude among pregnant women
attending the antenatal clinic the Hawassa Health Center.
Methods
Study population
A total of 139 pregnant women attending the routine
antenatal clinic of the Hawassa Health Center were
screened for GBS colonization from May 2010 through
June 2010. The approach was based on universal
screening of all pregnant women for GBS colonization
between 35 and 37 of weeks of gestation (11). Sample
size was calculated based on previous prevalence rates
reported from Ethiopia (10), with 95% confidence
interval, 0.05 margin of error, and a contingency of 10%.
Culture and identification of GBS
According to guidelines of the CDC (11) and the
American College of Obstetricians and Gynecologists
(12), swabs were taken from both the lower one third of
the vagina and the anal region using sterile cotton swabs
by the attending midwife and placed in Amies transport
medium (Oxoid, UK) and immediately transported to the
Microbiology Laboratory of Hawassa Referral Hospital
for culture.
The vaginal and ano-rectal swabs were placed into 1 ml
Todd-Hewitt broth (Oxoid, UK) supplemented with 10
µg/ml colistin and 15 µg/ml nalidixic acid (Biomerieux,
France) to prevent growth of contaminants. The broth
was incubated for 18–24
hours at 35-37oC and sub-cultured on 5% sheep blood
agar (Oxoid, UK) and incubated overnight in 5% CO2
atmosphere for 18-24 hours. All suspected GBS colonies
(pin point, with narrow beta-hemolysis) were sub-
cultured on blood agar and subjected for Gram stain and
catalase test.  All gram positive and catalase negative
cocci isolates were tested for CAMP test and latex
agglutination assay as a confirmatory testing for GBS
(Oxoid, UK).
Antimicrobial susceptibility testing
All procedures for disk susceptibility were performed
according to the methodologies described in the manual
of the Clinical and Laboratory Standards Institute (CLSI)
(13). Fresh subcultures of GBS were used after overnight
growth on blood agar plate (Oxoid, UK). The inoculums
were standardized by suspending colonies in sterile
phosphate buffered saline (pH 7.2) to achieve a turbidity
of 0.5 McFarland standards. A sterile cotton swab was
dipped into the bacterial suspension, elevated above the
liquid and rotated several times against the inside wall of
the tube to remove excess inoculums. Then the swab was
inoculated on Mueller–Hinton agar plate (Oxoid, UK)
supplemented with 5% de-fibrinated sheep blood to
obtain confluent growth; antibiotic disks were placed and
incubated at 35°C with 5% CO2 atmosphere for 20 hours.
Ten antibiotic disks (Oxoid) used were: penicillin G (P)
(10 IU), erythromycin (E) (15 µg), ceftriaxone (CRO)
(30 µg), gentamicin (CN) (10 µg), norfloxacin (NOR)
(10 µg), chloramphenicol (C) (30 µg), vancomycin (VA)
(30 µg), tetracycline (TE) (30 µg), ampicillin (AMP) (10
µg) and ciprofloxacin (CIP) (5 µg).
The zones of growth inhibition were measured to the
nearest whole millimeter using a sliding caliper. The
sizes of the inhibition zones were graded according to the
CLSI approved standard (13). Each isolate was classified
as susceptible, intermediate or resistant to each antibiotic
tested.
Quality control
To maintain the quality of data, pre-test was done before
the actual work to check the protocol for isolation of
GBS and the questionnaire. In actual work, every sample
was processed in triplicates and every result was cross
checked by the principal investigator and the co-
investigator.
Enterococcus faecalis (ATCC 29212), Staphylococcus
aureus (ATCC 24923), Streptococcus pyogenes (ATCC
19615) were used as quality control throughout the study
for culture and antimicrobial susceptibly testing. All the
strains were obtained from the Ethiopian Health and
Nutrition Research Institute (EHNRI).
Statistical analysis
Data entry and analysis was done using SPSS version
11.5software. Prevalence figures were calculated for the
total study population and separately by age groups. Chi-
square test was used to compare results between the
pregnant women with different age groups and with the
previous findings from the literature. P-value less than
0.05 were considered statistically significant.
Ethical Considerations
The research project was ethically cleared by the
Institutional Review Board (IRB), Faculty of Medicine of
Addis Ababa University. Official permission from the
study site as well as written informed consent from study
participants were also obtained.
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Results
Socio-demographic characteristics
The socio-demographic characteristics of 139 pregnant
women screened for GBS colonization are presented in
Table 1. The mean age of the participants was 25.6 years
ranging 17-40 years. The majority of the participants
were between the ages of 25-29 years (41.0%). Most of
them were from the Hawassa area (95.0%) and most of
them were house wives (91.4%) while the remaining
were students, teachers, and other.
Overall prevalence
Out of 139 pregnant women screened, 29 (20.9%) were
found to be colonized with GBS.
Risk factors analysis
Overall, no statistically significant association of GBS
colonization was observed in connection with any of the
socio- demographic characteristics of the study subjects
as shown in Table 2.
Table 1: Socio-demographic characteristics of 139
women investigated for GBS, at Hawassa Health








































Table 2: Variables associated/not associated with Group B Streptococcus colonization in
pregnant women, Hawassa Health center, Hawassa, Ethiopia June, 2010
Variables Total GBS
colonization
Percentages (%) P value
Age (in years)
15-19 9 4 44.4
0.48
20-24 51 8 15.7
25-29 57 12 21.1
30-34 17 4 23.5
35-39 3 1 33.3
40-44 2 0 0
Occupation
House wife 127 25 19.7
0.12
Teacher 3 0 0
Student 6 2 33.3
Lawyer 1 1 100
Accountant 1 1 100
Merchant 1 0 0
Address
Algie 1 0 0
0.49
Tikur wuha 4 1 25
Wondo 2 0 0
Hawassa 132 28 21.2
Type of Contraceptive use
Injectable 85 17 20
0.84
Pills 11 3 27.3
Injectable & pills 6 1 16.7
Loop 2 0 0
None 35 8 22.9
Number of ANC Visit
One  time 1 1 100
0.05
Two  times 19 4 21.1
Three times 21 8 38.1
Four times 98 16 16.3
Type of Gravida
Primigravida 39 7 17.95
0.59Multigravida 100 22 22
Antimicrobial susceptibility data
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The susceptibility pattern of 29 GBS isolated from
pregnant women against 10 antimicrobial agents is
presented in Table 3. All strains were susceptible to
penicillin, ampicillin, vancomycin and gentamicin.
Resistance was observed against erythromycin (6.9%),
tetracycline (48.2%), ceftriaxone (10.3%),
chloramphenicol (51.7%), ciprofloxacin (13.8%) and
norfloxacin (10.3%).
Table 3: Antimicrobial susceptibility pattern of 29 GBS isolated from pregnant women, of Hawassa Health
Center, Hawassa, Ethiopia (May 2010-June-2010)
Antibiotics Susceptible Intermediate Resistant
Penicillin G 100% (29/29) - -
Erythromycin 89.7% (26/29) 3.4% (1/29) 6.9% (2/29)
Tetracycline 39.3% (11/29) 14.3 (4/29) 48.2% (14/29)
Ampicillin 100% (29/29) - -
Vancomycin 100% (29/29) - -
Ceftriaxone 89.7% (26/29) - 10.3  (3/29)
Chloramphenicol 20.7% (6/29) 27.6% (8/29) 51.7% (15/29)
Ciprofloxacin 86.2% (25/29) - 13.8% (4/29)
Gentamicin 100% (29/29) - -
Norfloxacin 89.5% (26/29) - 10.3%(3/29)
Discussion
In the present study the overall prevalence of Group B
streptococcus (GBS) colonization among pregnant
women was found to be 20.9%. Similar findings have
been reported in other African countries such as in
Malawi, Egypt, Zimbabwe, Gambia, and Tanzania; the
prevalence of GBS in these countries ranges from 16.5-
23% (14-18).. However low colonization rate was
reported in a previous study conducted in Ethiopia (9%)
(10) and Mozambique (1.8%) (19).
Different studies conducted in Latin America and the
Caribbean also showed results similar to the present
study such as in Brazil (17-33%) (20-23). However lower
prevalence was reported in some Latin American
countries such as Peru (6%) (24) and Argentina (3.2%)
(25).
The rate of GBS colonization in this study is almost
similar to the findings reported in some European
countries. Two studies from Italy found a GBS
colonization rate of 17.9% (26), and 18% (27). Studies
from Poland and Switzerland also found a colonization
rate of 17.2% (28) and 21% (29), respectively. Another
study in a multicultural population of pregnant women in
the Netherlands also showed a colonization rate of 21%
(4).  However, lower GBS colonization rate have been
reported in some Mediterranean countries such as those
e.g. Istanbul and Elazin in Turkey giving 8% (30) and
8.7% (31), respectively. A study conducted in a city of
Northern Greece also found a low colonization rate of
6.6% (32).
Among 21 studies conducted in pregnant women in 13
European countries, GBS vaginal colonization rates
ranged from 6.5 to 36%, with one third of the studies
reporting rates of 20% or greater. The regional rates were
Eastern Europe 19.7–29.3%, Western Europe 11–21%,
Scandinavia 24.3–36%, and Southern Europe 6.5–32%
(33), which is in agreement with the present study.
The rates obtained in the present study one, more or less,
similar with findings reported from most Asian countries
like Thailand, 16-18% (34, 35), Iran 20-26% (36, 37) and
Saudi Arabia 27.6% (38). However, lower prevalence
rates were reported in by some Asian countries; in Hong
Kong 10.4% (39)  and Korea 3.9% (40), with similar
findings from Australia (12.9%) (41).
Knowledge about the risk factors contributing to GBS
colonization in pregnant women is relevant to minimize
the morbidity and mortality associated with maternal and
neonatal GBS infections. In the present study, no
statistically significant association was observed for GBS
colonization in the study subjects with any of the socio-
demographic characteristics as outlined in Table 2.
Similar findings have been reported in studies conducted
elsewhere (22, 24, 42). However studies conducted in
Athens and Hong Kong showed that GBS colonization
rate was high among pregnant women who work outside
their homes and those who had frequent visits of
antenatal clinics (32, 39).
In our study, the susceptibility pattern of 29 GBS isolated
from pregnant women against 10 antimicrobial agents is
presented in Table 3. All strains were susceptible to
penicillin, ampicillin, vancomycin and gentamicin.
However resistance was observed against
chloramphenicol (51.7%), tetracycline (44.8%),
erythromycin (6.9%), ceftriaxone (10.3%), ciprofloxacin
(13.8%) and norfloxacin (10.5%). Similar findings have
been reported in studies conducted in Tanzania (18),
USA (43, 44), Canada (45) and Lebanon (46).
The use of intra-partum antibiotics to prevent peri-natal
vertical transmission of GBS and early onset neonatal
sepsis has increased significantly since the Center for
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Disease Control (CDC) published guidelines in 1996 and
to increase the efficiency of the existing guideline, the
revised one was released in 2002. The antibiotic of
choice is either penicillin G or ampicillin (44).
The current CDC guidelines recommend that patients not
allergic to penicillin should receive penicillin or
ampicillin. Individuals with a minor allergy to penicillin
should receive cefazolin while individuals with a major
allergy should receive clindamycin or vancomycin if
GBS is known to be sensitive for those antibiotics (44).
One of the limitations of the present study is that sero-
typing of GBS was not done because of the lack of anti-
sera. GBS can be sub-typed into 9 serotypes; type Ia, Ib, I
a/c, I b/c, II, III, IV, V and VI based on their capsular
polysaccharide using specific anti-sera. Knowledge about
the prevalent GBS-serotypes in a given country is very
important to develop and implement effective vaccine for
prevention of neonatal GBS disease. However, there is a
big difficulty in developing group B streptococcal
vaccines because of the existence of multiple serotypes in
different locations and geographic variations in serotype
distribution (47).
In conclusion, the present study revealed a colonization
rate of 20.9% with GBS among pregnant women
attending the antenatal clinic of the Hawassa Health
Center, Hawassa, Ethiopia. No statistically significant
association was observed with any of the socio-
demographic characteristics of the study subjects with
GBS colonization. All Resistance was observed against
erythromycin (6.9%), tetracycline (48.2%), ceftriaxone
(10.3%), chloramphenicol (51.7%), ciprofloxacin
(13.8%) and norfloxacin (10.3%).  Large- scale
epidemiological studies should be carried out in different
parts of the country in order to know the actual GBS
colonization rate and GBS serotypes. Further,
assessment of risk factors associated with maternal GBS
colonization is required.  As more data regarding GBS
and its serotypes in Ethiopia became available, it is
possible to consider implementation of prevention
guideline used by other countries.  In the long run it is
also possible to develop vaccine to prevent early onset
neonatal disease caused by GBS.
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